150 related articles for article (PubMed ID: 32710610)
1. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells.
García-Venzor A; Mandujano-Tinoco EA; Ruiz-Silvestre A; Sánchez JM; Lizarraga F; Zampedri C; Melendez-Zajgla J; Maldonado V
Carcinogenesis; 2020 Nov; 41(11):1485-1497. PubMed ID: 32710610
[TBL] [Abstract][Full Text] [Related]
2. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer.
Roscigno G; Puoti I; Giordano I; Donnarumma E; Russo V; Affinito A; Adamo A; Quintavalle C; Todaro M; Vivanco MD; Condorelli G
Oncotarget; 2017 Mar; 8(12):19507-19521. PubMed ID: 28061479
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment-regulated lncRNA-HAL is able to promote stemness in breast cancer cells.
García-Venzor A; Mandujano-Tinoco EA; Lizarraga F; Zampedri C; Krötzsch E; Salgado RM; Dávila-Borja VM; Encarnación-Guevara S; Melendez-Zajgla J; Maldonado V
Biochim Biophys Acta Mol Cell Res; 2019 Dec; 1866(12):118523. PubMed ID: 31401107
[TBL] [Abstract][Full Text] [Related]
4. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
Peng F; Wang JH; Fan WJ; Meng YT; Li MM; Li TT; Cui B; Wang HF; Zhao Y; An F; Guo T; Liu XF; Zhang L; Lv L; Lv DK; Xu LZ; Xie JJ; Lin WX; Lam EW; Xu J; Liu Q
Oncogene; 2018 Feb; 37(8):1062-1074. PubMed ID: 29106390
[TBL] [Abstract][Full Text] [Related]
5. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.
Syu JP; Chi JT; Kung HN
Oncotarget; 2016 Mar; 7(12):14659-72. PubMed ID: 26894974
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
[TBL] [Abstract][Full Text] [Related]
8. Senescence evasion by MCF-7 human breast tumor-initiating cells.
Karimi-Busheri F; Rasouli-Nia A; Mackey JR; Weinfeld M
Breast Cancer Res; 2010; 12(3):R31. PubMed ID: 20525204
[TBL] [Abstract][Full Text] [Related]
9. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
Deng Y; Guo W; Xu N; Li F; Li J
Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
[TBL] [Abstract][Full Text] [Related]
10. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ.
Yang W; Yang X; Wang X; Gu J; Zhou D; Wang Y; Yin B; Guo J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):4921-4932. PubMed ID: 31245927
[TBL] [Abstract][Full Text] [Related]
11. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment.
Reynolds DS; Tevis KM; Blessing WA; Colson YL; Zaman MH; Grinstaff MW
Sci Rep; 2017 Sep; 7(1):10382. PubMed ID: 28871147
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors.
Semenza GL
Clin Sci (Lond); 2015 Dec; 129(12):1037-45. PubMed ID: 26405042
[TBL] [Abstract][Full Text] [Related]
14. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines.
Fujiwara D; Kato K; Nohara S; Iwanuma Y; Kajiyama Y
Biochem Biophys Res Commun; 2013 May; 434(4):773-8. PubMed ID: 23602898
[TBL] [Abstract][Full Text] [Related]
16. Effects of Intermittent Hypoxia on Expression of Glucose Metabolism Genes in MCF7 Breast Cancer Cell Line.
Jarrar Y; Zihlif M; Al Bawab AQ; Sharab A
Curr Cancer Drug Targets; 2020; 20(3):216-222. PubMed ID: 31738135
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of cisplatin-induced cytotoxicity against cervical cancer spheroid cells by targeting long non-coding RNAs.
Li M; Lu B; Dong X; Zhou Y; He Y; Zhang T; Bao L
Pathol Res Pract; 2019 Nov; 215(11):152653. PubMed ID: 31570280
[TBL] [Abstract][Full Text] [Related]
18. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
He X; Xiao X; Dong L; Wan N; Zhou Z; Deng H; Zhang X
Tumour Biol; 2015 Mar; 36(3):2065-75. PubMed ID: 25394901
[TBL] [Abstract][Full Text] [Related]
19. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
[TBL] [Abstract][Full Text] [Related]
20. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
